Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines (PRAX) granted inducement restricted stock unit awards covering 11,535 shares of common stock to sixty-six new non-executive employees on September 1, 2026.

Rhea-AI Summary

Praxis Precision Medicines (PRAX) granted inducement restricted stock unit awards covering 11,535 shares of common stock to sixty-six new non-executive employees on September 1, 2026. These awards were issued under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used solely for equity awards to individuals who were not previously employed by Praxis, or after a bona fide break in service, as an inducement to join the company. The restricted stock units will vest in four equal annual installments, subject to each employee’s continued employment on the applicable vesting dates.

Argus Sep 4 session

-0.94% close to close Open Argus

Details

News Market Reaction – PRAX

On Sep 4, the first trading day after this news, PRAX closed 0.94% below the previous close.

Data tracked by StockTitan Argus for the Sep 4 session.

Key Figures

RSU shares: 11,535 shares New employees: 66 employees Grant date: September 1, 2026 +1 more

RSU shares

11,535 shares

September 1, 2026 inducement grants

New employees

66 employees

Non-executive employees receiving awards

Grant date

September 1, 2026

Compensation Committee award date

Vesting schedule

4 equal annual installments

Subject to continued employment

Historical Context

5 past events · Latest: Aug 06

5 events

1. Aug 06

   Earnings report

   24h Move

   +15.9%

   Second-quarter results included regulatory progress and cash runway extending into 2028.

2. Aug 04

   Inducement grants

   24h Move

   +3.0%

   RSU awards covered 7,318 shares for 29 new non-executive employees.

3. Jul 30

   Earnings scheduling

   24h Move

   +0.0%

   The company scheduled second-quarter results and its corporate update for August 6.

4. Jul 07

   Partnership agreement

   24h Move

   +3.3%

   Praxis and Remagine Labs announced a transdermal ulixacaltamide development collaboration.

5. Jul 02

   Inducement grants

   24h Move

   -1.6%

   RSUs covered 951 shares for five new non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, inducement plan, nasdaq listing rule 5635(c)(4)

3 terms

restricted stock units financial

"The restricted stock units will vest in four equal annual installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

inducement plan financial

"under the Praxis Precision Medicines, Inc. 2024 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 11,535 shares of its common stock to sixty-six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity grants did Praxis Precision Medicines (PRAX) announce on September 3, 2026?

Praxis Precision Medicines announced that on September 1, 2026, its Compensation Committee granted restricted stock unit awards covering an aggregate of 11,535 shares of common stock to sixty-six new non-executive employees as inducement awards.

Under which plan were the new Praxis (PRAX) inducement RSUs granted?

The inducement restricted stock unit awards were granted under the Praxis Precision Medicines 2024 Inducement Plan. The plan is used exclusively for equity awards to individuals who were not previously employees, or after a bona fide period of non-employment, as an inducement to enter employment.

How do the Praxis (PRAX) inducement restricted stock units vest for new employees?

The restricted stock units granted to the sixty-six new non-executive employees will vest in four equal annual installments. Vesting is subject to each employee’s continued employment with Praxis on each applicable vesting date.

Why were the Praxis (PRAX) inducement RSUs granted under Nasdaq Listing Rule 5635(c)(4)?

The company states that the restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis, in accordance with Nasdaq Listing Rule 5635(c)(4), which permits such equity grants to new employees outside shareholder-approved plans.

Who is eligible to receive awards under the Praxis 2024 Inducement Plan (PRAX)?

The 2024 Inducement Plan is used exclusively for equity awards to individuals who were not previously employees of Praxis, or who return after a bona fide period of non-employment, as an inducement material to those individuals entering into employment with the company.